Evidence map›Paper›PMID 40848115›Full record

ArticleInternational journal of clinical pharmacy2026

Colorectal cancer patients' experiences with antineoplastic agents from the perspective of their significant others: a longitudinal qualitative study.

Alison Brincat, Antonella Tonna, Patricia Vella Bonanno, Derek Stewart, Anita Elaine Weidmann

Abstract read
In one paragraph

Article in International journal of clinical pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alison BrincatSchool of Pharmacy, Applied Sciences and Public Health, Robert Gordon University, Aberdeen, Scotland. alison.brincat@gmail.com.ORCID http://orcid.org/0000-0002-5670-2736
Antonella TonnaSchool of Pharmacy, Applied Sciences and Public Health, Robert Gordon University, Aberdeen, Scotland.
Patricia Vella BonannoDepartment of Health Systems Management and Leadership, Faculty of Health Sciences, University of Malta, Msida, Malta.
Derek StewartSchool of Pharmacy, Applied Sciences and Public Health, Robert Gordon University, Aberdeen, Scotland.
Anita Elaine WeidmannInstitute of Pharmacy, Department of Clinical Pharmacy, Innsbruck University, Innsbruck, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundColorectal cancer and its treatment deeply impact patients' lives. Significant others, often family members, play crucial pre-existing roles in patients' lives and are closely involved in their care. However, there is limited understanding of the patients' treatment journey from the significant others' perspective.

aimTo explore colorectal cancer patients' experiences with antineoplastic agents from the perspective of significant others over 24 weeks.

methodThis involved a longitudinal qualitative study with 16 significant others nominated by patients with colorectal cancer. Two in-depth interviews were conducted: one at start and another after 24 weeks of treatment. Interviews were audio-recorded, transcribed and thematically analysed by 2 researchers independently.

resultsFive themes were identified: Patients' perceptions and knowledge of the illness and treatment, the healthcare system in relation to the illness and treatment, patients' involvement in treatment decision-making and their experience of medicine-taking, medicine and illness-related impact on patients and others and personal support structures. Significant others observed that patients initially viewed treatment as curative but later perceived as means to extend life-expectancy. While significant others considered that concerns about aesthetics were initially prominent for the patient, fatigue and peripheral neuropathy became most impactful effects. They considered patients' experiences with cancer services to remain overall positive, particularly regarding personalised support from nurse navigators. Significant others noted that early establishment of support network was crucial for fostering resilience throughout the treatment journey.

conclusionThis study provides insights from significant others highlighting the complex evolution of patients' experiences and importance of establishing a personalised support network early in treatment journey.

Indexed as

Antineoplastic AgentsColorectal NeoplasmsFamilyAdultAgedAged, 80 and overFemaleHealth Knowledge, Attitudes, PracticeHumansLongitudinal StudiesMaleMiddle AgedQualitative ResearchAntineoplastic AgentsAntineoplastic agentsColorectal cancerLongitudinal studyPatients’ experiencesSignificant others

Identifiers

PMID40848115
PMCPMC12823761

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.